On March 31st, innovative drug concept stocks exploded in the afternoon, with new CAR-T technology as the core catalyst

1、 Plate Movement: Multiple Stocks Rise Strong, Activity Highlighting

On the afternoon of March 31st, innovative drug concept stocks collectively made efforts, and the sector as a whole showed an active trend. Among them, Haichuang Pharmaceutical - U performed outstandingly, with an intraday increase of over 11%, and the stock price continued to rise, driving the popularity of the sector; Jinyao Pharmaceutical and Kailaiying rose by the daily limit, with stable order closures, becoming the leading market leaders in the sector; Several related stocks, including Shuanglu Pharmaceutical, followed suit and formed a linkage effect, driving the overall rise of the innovative drug sector and becoming one of the most dynamic sectors in the afternoon market.

From the performance of the market, the active sector this time presents the characteristics of "leading by leaders and blooming from multiple points". There are both stocks that have driven sentiment by the daily limit up, as well as stocks that have steadily risen, reflecting a significant increase in market funds' attention to the field of innovative drugs and an enhanced willingness to allocate funds. Combined with the recent overall recovery trend of the pharmaceutical sector, the abnormal movement of innovative drug concept stocks further continues the strong performance of the sector.

2、 Core catalysis: Breakthrough in new CAR-T technology, opening up new space in the industry

The innovative drug concept stocks were active in the afternoon, driven by a key technological breakthrough. According to the news, a team from Karolinska Institute in Sweden has successfully developed a novel chimeric antigen receptor T cell (CAR-T) generation technology, providing a new approach for cancer immunotherapy. CAR-T technology, as an important direction of cancer immunotherapy, has always been a research and development hotspot in the field of innovative drugs. The emergence of this new technology is expected to break through the limitations of traditional CAR-T technology, improve treatment efficacy, reduce treatment risks, and bring new breakthroughs to cancer treatment.

It is reported that traditional CAR-T technology has problems such as complex preparation, high cost, and obvious side effects in clinical applications. However, the new technology developed by the Swedish team has improved cell generation efficiency, safety, and other aspects, which is expected to promote the clinical popularization of CAR-T technology and further open up the development space of the cancer immunotherapy market. Stimulated by this positive news, market funds quickly poured into related innovative drug concept stocks, driving the sector to quickly become active in the afternoon.

3、 Market interpretation: Technological breakthroughs+sector recovery, industry prosperity improvement

The fluctuation of innovative drug concept stocks this time is the result of the resonance between technological breakthroughs and the overall recovery of the sector. From the perspective of industry background, the pharmaceutical sector has recently experienced multiple benefits, with biopharmaceuticals being elevated to the level of an emerging pillar industry. Policies have shifted from "cost control" to "supporting innovation and strengthening supply", and the renewal and price reduction of innovative drugs have narrowed, resulting in improved approval efficiency and creating a favorable environment for industry development. At the same time, the overseas trading of innovative drugs continues to heat up, and domestic innovative assets have gained global market recognition, further boosting confidence in the sector.